• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by 8i Acquisition 2 Corp.

    11/25/22 4:05:32 PM ET
    $LAX
    Get the next $LAX alert in real time by email
    SC 13D 1 formsc13d.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934

     

    EUDA Health Holdings Limited

     

    (Name of Company)

     

    Ordinary Shares, no par value

     

    (Title of Class of Securities)

     

    G3142E105

     

    (CUSIP)

     

    Wei Wen Kelvin Chen

    Chief Executive Officer

    1 Pemimpin Drive #12-07

    One Pemimpin Singapore 576151

    Tel: +65-6268 6821

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    November 17, 2022

     

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 240.13d-1(e), 240.13d-1(f) or 140.13d-1(g), check the following box ☐

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be ‘filed’ for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however see the Notes).

     

     

     

     

     

     

    CUSIP Number: G3142E105

     

    1 NAME OF REPORTING PERSON
       
      Watermark Developments Limited
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
         
      (a) ☐
      (b) ☐
    3 SEC USE ONLY
       
    4 SOURCE OF FUNDS
       
      OO
    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) ☐
       
    6 CITIZENSHIP OR PLACE OF ORGANIZATION
       
      British Virgin Islands

      7 SOLE VOTING POWER
         
        9,660,000 Ordinary Shares (1) (2)
    NUMBER OF    
    SHARES 8 SHARED VOTING POWER
    BENEFICIALLY    
    OWNED BY   0
    EACH    
    REPORTING 9 SOLE DISPOSITIVE POWER
    PERSON WITH    
        9,660,000 Ordinary Shares (1) (2)
         
      10 SHARED DISPOSITIVE POWER
         
        0

    11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
      9,660,000 Ordinary Shares (1) (2)
    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW(11) EXCLUDES CERTAIN SHARES ☐
       
    13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
       
      47.84% of Ordinary Shares (3)
    14 TYPE OF REPORTING PERSON
       
      CO

     

    (1) Each Ordinary Share is entitled to one vote per share.
    (2) 9,660,000 Ordinary Shares are issued to the Reporting Person at closing of the Business Combination (as defined below).
    (3) The calculations in the table below are based on 20,191,770 Ordinary Shares outstanding as of November 25, 2022.

     

     

     

     

    Item 1. Security and Issuer.

     

    This Schedule 13D relates to the Ordinary Shares, no par value of EUDA Health Holdings Limited, a British Virgin Islands exempted company whose principal executive office is located at 1 Pemimpin Drive #12-07, One Pemimpin Singapore 576151.

     

    Item 2. Identity and Background.

     

    This Schedule 13D is filed by Watermark Developments Limited, a British Virgin Islands business company, whose executive officers, directors, and controlling persons are:

     

    Wei Wen Kelvin Chen, Director

    Residence/business address: c/o EUDA Health Holdings Limited, 1 Pemimpin Drive #12-07,

    One Pemimpin Singapore 576151.

    Occupation/employment: Executive Officer

    Name, principal business and address of the employer: EUDA Health Holdings Limited, 1 Pemimpin Drive

    #12-07, One Pemimpin Singapore 576151.

     

    Wilke Service Limited, Director

    Place of organization: Seychelles

    Principal business: Investments

    Address of the principal office: Suite 9, Ansuya Estate, Revolution Avenue Victoria, Mahe, Seychelles

     

    The Reporting Person and its executive officers, directors, and controlling persons, have not, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

    The Reporting Person and its executive officers, directors, and controlling persons, have not, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or state securities laws or finding any violation with respect to such laws.

     

     

     

     

    Item 3. Source and Amount of Funds and Other Consideration.

     

    1,500,000 shares of Common Stock of EUDA Health Limited

     

    Item 4. Purpose of Transaction.

     

    The Reporting Person acquired the Ordinary Shares as a result of a business combination among the Reporting Person, the Issuer, and a subsidiary of the Reporting Person, EUDA Health Limited, a British Virgin Islands business company, as disclosed in the Issuer’s proxy statement on Schedule 14A filed pursuant to Section 14(a) of the Securities Exchange Act of 1934 on the SEC on October 13, 2022, as amended (the “Business Combination”).

     

    Except as provided herein, the Reporting Person does not have any current plans or proposals that would be related to or would result in any of the matters described in Items (a) through (j) of Item 4 of Schedule 13D; provided, however, that as part of his ongoing evaluation of his investment in the Issuer and investment alternatives, the Reporting Person may consider such matters in the future and, subject to applicable law or other restrictions, may formulate other purposes, plans or proposals regarding the Issuer or the common stock that may be deemed to be beneficially owned by the Reporting Person, or take any other actions that could involve one or more of the types of transactions or have one or more of the results described in clauses (a) through (j) of Item 4 of Schedule 13D.

     

    Item 5. Interest in Securities of the Company.

     

      (a) The aggregate number and percentage of shares of the Issuer’s ordinary shares to which this Schedule 13D relates is 9,660,000 ordinary shares held by the Reporting Person. The Reporting Person holds 47.84% of the Issuer’s outstanding ordinary shares.
         
      (b) The Reporting Person holds sole power to dispose of the 9,660,000 ordinary shares.
         
      (c) Other than the transaction described herein there has been no other transactions concerning the ordinary shares of the Issuer effected during the past sixty (60) days.
         
      (d) No other person is known to the Reporting Person to have the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, the 9,660,000 ordinary shares.
         
      (e) Not applicable.

     

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Company.

     

    The information set forth in Item 4 of this Schedule 13D is hereby incorporated by reference into this Item 6, as applicable.

     

    Other than the foregoing agreements and arrangements, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the Reporting Person and any other person with respect to any securities of the Issuer, including, but not limited to transfer or voting of any of the securities, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.

     

    Item 7. Material to be Filed as Exhibits.

     

    Not applicable.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

      Date: November 25, 2022
       
      Watermark Developments Limited
       
      By: /s/ Wei Wen Kelvin Chen
        Wei Wen Kelvin Chen
        Director

     

     

     

    Get the next $LAX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LAX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chen Wei Wen Kelvin

    4 - EUDA Health Holdings Ltd (0001847846) (Issuer)

    6/20/23 3:19:26 PM ET
    $LAX

    SEC Form 3: New insider Wong Kongyew claimed no ownership of stock in the company

    3 - EUDA Health Holdings Ltd (0001847846) (Issuer)

    6/8/23 8:31:59 PM ET
    $LAX

    SEC Form 4 filed by Chen Wei Wen Kelvin

    4 - EUDA Health Holdings Ltd (0001847846) (Issuer)

    5/26/23 8:42:17 AM ET
    $LAX

    $LAX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    8i Acquisition 2 Corp. and EUDA Health Ltd Complete Business Combination

    Singapore, Nov. 23, 2022 (GLOBE NEWSWIRE) -- 8i Acquisition 2 Corp. (the "Company" or "LAX") (NASDAQ:LAX), a publicly traded special purpose acquisition company, today announced the completion of its business combination (the "Business Combination") with EUDA Health Ltd ("EUDA Health"), a Singapore-based digital health platform that aims to make healthcare more affordable, accessible, and improve the patient experience by delivering improved outcomes through personalized healthcare. The combined company will operate under the name "EUDA Health Holdings Limited" (NASDAQ:EUDA) and will be led by Founder and Chief Executive Officer Dr. Kelvin Chen. Commencing at the open of trading on N

    11/23/22 4:32:15 PM ET
    $LAX

    8i Acquisition 2 Corp. and EUDA Health Limited Complete Business Combination

    Singapore, Nov. 17, 2022 (GLOBE NEWSWIRE) -- 8i Acquisition 2 Corp. (the "Company" or "LAX") (NASDAQ:LAX), a publicly traded special purpose acquisition company, today announced the completion of its business combination (the "Business Combination") with EUDA Health Limited ("EUDA Health"), a Singapore-based digital health platform that aims to make healthcare more affordable, accessible, and improve the patient experience by delivering improved outcomes through personalized healthcare. The combined company will operate under the name "EUDA Health Holdings Limited" and will be led by Founder and Chief Executive Officer Dr. Kelvin Chen. Commencing at the open of trading on November 18, 202

    11/17/22 5:23:47 PM ET
    $LAX

    8i Acquisition 2 Corp. Announces Approval of Business Combination and Ability of Shareholders to Withdraw Ordinary Shares Tendered for Redemption

    Singapore, Nov. 10, 2022 (GLOBE NEWSWIRE) -- 8i Acquisition 2 Corp. (NASDAQ:LAX, the "Company"))), a special purpose acquisition company, announced today that all proposals presented to shareholders at the special meeting of shareholders held on November 10, 2022 at 10:00 a.m. Eastern Time relating to the Company's business combination with EUDA Health Limited were approved by shareholders. Holders of Company's ordinary shares that elected to redeem shares in connection with the Company's special meeting of shareholders may withdraw such redemption requests by no later than 5:00 p.m. Eastern Time on November 11, 2022. Based on a total of 8,195,770 ordinary shares tendered for redemption in

    11/10/22 4:01:00 PM ET
    $LAX

    $LAX
    SEC Filings

    View All

    SEC Form 6-K filed by 8i Acquisition 2 Corp.

    6-K - EUDA Health Holdings Ltd (0001847846) (Filer)

    1/22/24 9:30:30 PM ET
    $LAX

    SEC Form 6-K filed by 8i Acquisition 2 Corp.

    6-K - EUDA Health Holdings Ltd (0001847846) (Filer)

    1/17/24 6:10:06 AM ET
    $LAX

    SEC Form 6-K filed by 8i Acquisition 2 Corp.

    6-K - EUDA Health Holdings Ltd (0001847846) (Filer)

    12/29/23 5:03:20 PM ET
    $LAX

    $LAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by 8i Acquisition 2 Corp. (Amendment)

    SC 13D/A - EUDA Health Holdings Ltd (0001847846) (Subject)

    5/26/23 8:44:16 AM ET
    $LAX

    SEC Form SC 13G/A filed by 8i Acquisition 2 Corp. (Amendment)

    SC 13G/A - EUDA Health Holdings Ltd (0001847846) (Subject)

    2/14/23 10:13:57 AM ET
    $LAX

    SEC Form SC 13G/A filed by 8i Acquisition 2 Corp. (Amendment)

    SC 13G/A - EUDA Health Holdings Ltd (0001847846) (Subject)

    2/7/23 4:59:19 PM ET
    $LAX